Literature DB >> 11160454

Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit.

Y Miyamoto1, K Yamada, Y Noda, H Mori, M Mishina, T Nabeshima.   

Abstract

NMDA receptors, an ionotropic subtype of glutamate receptors (GluRs) forming high Ca(2+)-permeable cation channels, are composed by assembly of the GluRzeta subunit (NR1) with any one of four GluRepsilon subunits (GluRepsilon1-4; NR2A-D). In the present study, we investigated neuronal functions in mice lacking the GluRepsilon1 subunit. GluRepsilon1 mutant mice exhibited a malfunction of NMDA receptors, as evidenced by alterations of [(3)H]MK-801 binding as well as (45)Ca(2+) uptake through the NMDA receptors. A postmortem brain analysis revealed that both dopamine and serotonin metabolism were increased in the frontal cortex and striatum of GluRepsilon1 mutant mice. The NMDA-stimulated [(3)H]dopamine release from the striatum was increased, whereas [(3)H]GABA release was markedly diminished in GluRepsilon1 mutant mice. When (+)bicuculline, a GABA(A) receptor antagonist, was added to the superfusion buffer, NMDA-stimulated [(3)H]dopamine release was significantly increased in wild-type, but not in the mutant mice. GluRepsilon1 mutant mice exhibited an increased spontaneous locomotor activity in a novel environment and an impairment of latent learning in a water-finding task. Hyperlocomotion in GluRepsilon1 mutant mice was attenuated by treatment with haloperidol and risperidone, both of which are clinically used antipsychotic drugs, at doses that had no effect in wild-type mice. These findings provide evidence that NMDA receptors are involved in the regulation of behavior through the modulation of dopaminergic and serotonergic neuronal systems. In addition, our findings suggest that GluRepsilon1 mutant mice are useful as an animal model of psychosis that is associated with NMDA receptor malfunction and hyperfunction of dopaminergic and serotonergic neuronal systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160454      PMCID: PMC6763826     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  52 in total

1.  Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

Authors:  A K Malhotra; D A Pinals; C M Adler; I Elman; A Clifton; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1997-09       Impact factor: 7.853

2.  NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus.

Authors:  A Imperato; M G Scrocco; S Bacchi; L Angelucci
Journal:  Eur J Pharmacol       Date:  1990-10-23       Impact factor: 4.432

3.  Reduced spontaneous activity of mice defective in the epsilon 4 subunit of the NMDA receptor channel.

Authors:  K Ikeda; K Araki; C Takayama; Y Inoue; T Yagi; S Aizawa; M Mishina
Journal:  Brain Res Mol Brain Res       Date:  1995-10

4.  Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death.

Authors:  D Forrest; M Yuzaki; H D Soares; L Ng; D C Luk; M Sheng; C L Stewart; J I Morgan; J A Connor; T Curran
Journal:  Neuron       Date:  1994-08       Impact factor: 17.173

5.  Disruption of selective attention by apomorphine, but not amphetamine, in the Mongolian gerbil.

Authors:  M L Cheal
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 6.  Schizophrenia and glutamatergic transmission.

Authors:  C A Tamminga
Journal:  Crit Rev Neurobiol       Date:  1998

7.  Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.

Authors:  R R Gainetdinov; W C Wetsel; S R Jones; E D Levin; M Jaber; M G Caron
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

8.  Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain.

Authors:  J Glowinski; L L Iversen
Journal:  J Neurochem       Date:  1966-08       Impact factor: 5.372

9.  Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.

Authors:  K Kitaichi; K Yamada; T Hasegawa; H Furukawa; T Nabeshima
Journal:  Jpn J Pharmacol       Date:  1994-10

10.  Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

Authors:  J E Leysen; P M Janssen; A A Megens; A Schotte
Journal:  J Clin Psychiatry       Date:  1994-05       Impact factor: 4.384

View more
  43 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 3.  The Functional and Molecular Properties, Physiological Functions, and Pathophysiological Roles of GluN2A in the Central Nervous System.

Authors:  Yongjun Sun; Xiaokun Cheng; Linan Zhang; Jie Hu; You Chen; Liying Zhan; Zibin Gao
Journal:  Mol Neurobiol       Date:  2016-01-21       Impact factor: 5.590

Review 4.  Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?

Authors:  Craig M Powell; Tsuyoshi Miyakawa
Journal:  Biol Psychiatry       Date:  2006-06-15       Impact factor: 13.382

5.  Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function.

Authors:  Gary E Duncan; Sheryl S Moy; Jeffery A Lieberman; Beverly H Koller
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

6.  A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice.

Authors:  Noboru Hiroi; Hongwen Zhu; Moonsook Lee; Birgit Funke; Makoto Arai; Masanari Itokawa; Raju Kucherlapati; Bernice Morrow; Takehito Sawamura; Soh Agatsuma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

7.  Disruption of the ether-a-go-go K+ channel gene BEC1/KCNH3 enhances cognitive function.

Authors:  Akira Miyake; Shinji Takahashi; Yukihiro Nakamura; Kohei Inamura; Shun-Ichiro Matsumoto; Shinobu Mochizuki; Masao Katou
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

8.  Noradrenergic refinement of glutamatergic neuronal circuits in the lateral superior olivary nucleus before hearing onset.

Authors:  Kenzo Hirao; Kei Eto; Yoshihisa Nakahata; Hitoshi Ishibashi; Taku Nagai; Junichi Nabekura
Journal:  J Neurophysiol       Date:  2015-07-22       Impact factor: 2.714

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

10.  Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour.

Authors:  Sachiko Taniguchi; Takanobu Nakazawa; Asami Tanimura; Yuji Kiyama; Tohru Tezuka; Ayako M Watabe; Norikazu Katayama; Kazumasa Yokoyama; Takeshi Inoue; Hiroko Izumi-Nakaseko; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura; Hisashi Umemori; Takafumi Inoue; Niall P Murphy; Kouichi Hashimoto; Masanobu Kano; Toshiya Manabe; Tadashi Yamamoto
Journal:  EMBO J       Date:  2009-10-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.